Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~* Presence of inoperable tumor lesion/s from histologically confirmed solid tumors or lymphomas, in patients with at least one lesion ≥ 1 cm and suitable for intra-lesional injection, who have disease progression after treatment with available therapies, or who are intolerant to such treatments~* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2~* If the patient received previous radiation therapy, the total absorbed radiation dose at the bone marrow level must be ≤ 1 Gy~* Life expectancy of at least 3 months~* Total tumor burden requiring ≤ 75 mL AvidinOX injection~* Clotting parameters within normal limits or maximum 25% outside of the the normal ranges~* Haematological and liver function test results ≤ grade 2 toxicity (according to US National Cancer Institute's Common Terminology) Criteria for Adverse Events v4.03 \[CTCAE~* Urine protein (dipstick): negative or trace; in case of trace, a urinalysis has to be performed in the local laboratory and have to confirm that such abnormality is not to be considered clinically significant, according to the investigator's judgement~* Creatinine ≤ 1.7 mg/dL~* eGFR\> 60% of mean age adjusted normal values~* Written informed consent~Main Exclusion Criteria:~* Known hypersensitivity to Avidin or AvidinOX (e.g. hen egg)~* Known hypersensitivity to ST2210 (DOTA biotin) or any excipient.~* Presence of unreachable (e.g. located in a region that cannot be reached by needle) or untreatable tumor lesions so that the benefit from the treatment of the treatable lesions does not justify patient's inclusion~* Active infection at screening or history of severe infection within the previous 3 months, if clinically relevant at screening as considered by the investigator~* Known human immunodeficiency virus (HIV) positive serology or chronically active hepatitis B or C.~* Administration of another investigational medicinal product within 30 days before the screening period.~* Patient who underwent chemotherapy, radiation therapy within 15 days before the screening period~* Previous treatment with any radiopharmaceutical within a period corresponding to 8 half-lives of the radionuclide used for labeling the respective radiopharmaceutical prior to the administration of study drug.~* Women of child-bearing potential without a serum negative pregnancy test and not willing to refrain from sexual activity or to utilize an adeguate contraceptive methods during all the course of the study~* Men unwilling to use appropriate contraceptive methods during the study and up to six months follow-up period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AvidinOX/177Lu-ST2210 (Type: EXPERIMENTAL): Patients will receive an intralesion injection of AvidinOX followed by two intravenous infusions of 177Lu- ST2210 with a distance of 14 days between them

Based on this trial design, predict the completion outcome and termination type (if applicable).